Iovance Biotherapeutics (NASDAQ: IOVA) disclosed:

On May 18, 2021, Maria Fardis, Ph.D., the Chief Executive Officer (“CEO”) of Iovance Biotherapeutics, Inc. (the “Company”), notified the Company that she will be resigning as President, CEO and a director of the Company to pursue other opportunities. The Company will immediately begin a search for a successor. In the meantime, effective upon Dr. Fardis’ departure, the Board of Directors of the Company will appoint Frederick G. Vogt, Ph.D., the Company’s current General Counsel, as the Company’s interim President and CEO.